Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Flutamide
Drug ID BADD_D00943
Description An antiandrogen with about the same potency as cyproterone in rodent and canine species.
Indications and Usage For the management of locally confined Stage B2-C and Stage D2 metastatic carcinoma of the prostate
Marketing Status approved; investigational
ATC Code L02BB01
DrugBank ID DB00499
KEGG ID D00586
MeSH ID D005485
PubChem ID 3397
TTD Drug ID D0Y0SW
NDC Product Code 69097-915; 80725-600; 44657-0048; 60429-272; 12780-4750; 44657-0056; 49884-753; 53104-7536
UNII 76W6J0943E
Synonyms Flutamide | Niftolid | Niftolide | Chimax | Cytamid | Eulexin | Euflex | Drogenil | Eulexine | Fluken | Flulem | Flumid | Fluta 1A Pharma | Fluta-cell | Fluta cell | Flutacell | Fluta-GRY | Fluta GRY | FlutaGRY | Flutamin | Flutandrona | Flutaplex | Flutexin | Fugerel | Grisetin | Novo-Flutamide | Novo Flutamide | NovoFlutamide | Oncosal | PMS-Flutamide | PMS Flutamide | Prostacur | Prostica | Prostogenat | SCH-13521 | SCH 13521 | SCH13521 | Testotard | Apimid | Apo-Flutamide | Apo Flutamide | ApoFlutamide
Chemical Information
Molecular Formula C11H11F3N2O3
CAS Registry Number 13311-84-7
SMILES CC(C)C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Galactorrhoea05.03.04.002; 21.05.02.002---
Gynaecomastia05.05.02.003; 21.05.04.003--
Haematuria20.02.01.006; 21.10.01.018; 24.07.01.047--
Haemolytic anaemia01.06.03.002---
Headache17.14.01.001--
Hepatic encephalopathy09.01.03.006; 17.13.01.003---
Hepatic necrosis09.01.07.002--
Hepatitis09.01.07.004---
Herpes zoster11.05.02.003; 17.09.03.026; 23.11.05.005--
Hyperglycaemia05.06.02.002; 14.06.02.002--
Hypertension24.08.02.001--
Increased appetite08.01.09.027; 14.03.01.003---
Injection site irritation08.02.03.027; 12.07.03.027---
Insomnia17.15.03.002; 19.02.01.002--
Interstitial lung disease10.02.01.033; 22.01.02.003---
Jaundice01.06.04.004; 09.01.01.004; 23.03.03.030---
Jaundice cholestatic09.01.01.005---
Laboratory test abnormal13.18.01.001---
Leukopenia01.02.02.001---
Libido decreased19.08.03.001; 21.03.02.005--
Loss of libido19.08.03.003---
Lung disorder22.02.07.001---
Malaise08.01.01.003--
Menopausal symptoms21.02.02.002---
Methaemoglobinaemia01.05.01.002--
Nausea07.01.07.001--
Neoplasm16.16.02.001---
Neoplasm malignant16.16.01.001---
Nervousness19.06.02.003---
Oedema08.01.07.006; 14.05.06.010---
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene